We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

AIDIAN

Aidian, formerly Orion Diagnostica, is a Finnish-based IVD company with almost 50 years of experience in developing a... read more Featured Products: More products

Download Mobile App




New Assay Rapidly Detects Toxigenic C. difficile

By LabMedica International staff writers
Posted on 01 Jul 2015
Print article
The new Orion GenRead C. difficile kit provides simple, rapid detection of pathogenic Clostridium difficile in fecal samples in a wide range of laboratory settings using the CE-marked Orion GenRead instrument
The new Orion GenRead C. difficile kit provides simple, rapid detection of pathogenic Clostridium difficile in fecal samples in a wide range of laboratory settings using the CE-marked Orion GenRead instrument (Photo courtesy of AIDIAN Oy)
A new assay is available for simple, rapid detection of pathogenic Clostridium difficile in fecal samples using the CE-marked GenRead molecular diagnostics system.

C. difficile infection is rising at an accelerating rate, has become more severe and difficult to treat, and is now more common than healthcare-associated infections (HAIs) caused by methicillin-resistant Staphylococcus aureus (MRSA).

Orion Diagnostica Oy (Espoo, Finland) has launched Orion GenRead C. difficile kit, enabling fast and accurate detection directly from fecal samples. The test supports earlier treatment decisions by detecting strong positive samples in 15 minutes.

Orion GenRead tests are used on the GenRead instrument and are based on SIBA, Orion Diagnostica’s proprietary isothermal nucleic acid amplification technology. SIBA is a robust and highly specific technology that allows fast, continuous amplification of nucleic acids. The use of SIBA in assays combined with the Orion GenRead instrument and its intuitive user interface, enables C. difficile testing outside of traditional PCR laboratories. Together with the portable and easy-to-use GenRead instrument and the fast assay – testing is possible in a wide range of laboratories.

The CE-marked system, consisting of the instrument and the assay, is currently available through Orion Diagnostica’s dedicated distributor network in Europe.

Related Links:

Orion Diagnostica Oy
Orion GenRead system 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.